Skip to content
LPBN-Icon-v1 (1)
The Right Coast
A Member of the Law Professor Blogs Network

Relief, NeuroRx: RLF-100 helps critical COVID-19 patients

By Thomas A. Smith

TEL AVIV Critically ill COVID-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United States, two drug companies said Sunday.

Geneva-based Relief Therapeutics Holdings AG RFLB.S has a patent for RLF-100, or aviptadil, a synthetic form of a natural peptide that protects the lung. US-Israeli NeuroRx Inc. partnered with Relief to develop the drug in the United States.

via nypost.com